Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007873
Filing Date
2025-05-15
Accepted
2025-05-15 16:01:47
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20250331x10q.htm   iXBRL 10-Q 1469167
2 EX-31.1 otlk-20250331xex31d1.htm EX-31.1 9719
3 EX-32.1 otlk-20250331xex32d1.htm EX-32.1 6370
  Complete submission text file 0001558370-25-007873.txt   6930142

Data Files

Seq Description Document Type Size
4 EX-101.SCH otlk-20250331.xsd EX-101.SCH 45980
5 EX-101.CAL otlk-20250331_cal.xml EX-101.CAL 46909
6 EX-101.DEF otlk-20250331_def.xml EX-101.DEF 184957
7 EX-101.LAB otlk-20250331_lab.xml EX-101.LAB 364822
8 EX-101.PRE otlk-20250331_pre.xml EX-101.PRE 321361
69 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20250331x10q_htm.xml XML 1253787
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 25952413
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)